Research Article
RAD51 and XRCC3 Polymorphisms Are Associated with Increased Risk of Prostate Cancer
Table 5
Relationship between G allele for rs5030789 in RAD51 and rs1799796 in XRCC3 and clinicopathological characteristics of prostate cancer patients.
| Clinicopathological parameter | rs5030789 | rs1799796 | A | G | A | G |
| Age | | | | | ≤ 71 | 35 | 67 | 60 | 42 | > 71 | 24 | 72 | 41 | 55 | | OR = 1.567 (0.846-2.902) | OR = 1.916 (1.089-3.371) | p = 0.202 | p = 0.033 |
| PSAT (ng/ml) | | | < 4-10 | 34 | 68 | 53 | 49 | > 10 | 25 | 71 | 48 | 48 | | OR = 1.420 (0.768-2.624) | OR = 1.082 (0.619-1.889) | p = 0.335 | p = 0.887 |
| Free/total PSA (F/T PSA) | | | < 0.16 | 25 | 71 | 44 | 52 | ≥ 0.16 | 34 | 68 | 57 | 45 | | OR = 0.704 (0.381-1.301) | OR = 0.668 (0.381-1.170) | p = 0.335 | p = 0.203 |
| PSA Density (PSAD, ng/ml) | | | < 0.28 | 26 | 72 | 49 | 49 | ≥ 0.28 | 33 | 67 | 52 | 48 | | OR = 0.733 (0.397-1.352) | OR = 0.923 (0.529-1.612) | p = 0.399 | p = 0.888 |
| Prostate volume (ml) | | | < 48 | 31 | 61 | 52 | 40 | ≥ 48 | 28 | 78 | 49 | 57 | | OR = 1.416 (0.768-2.608) | OR = 1.512 (0.862-2.652) | p = 0.337 | p = 0.192 |
| Gleason score | | | < 7 | 19 | 37 | 37 | 19 | ≥ 7 | 40 | 102 | 64 | 78 | | OR = 1.309 (0.675-2.541) | OR = 2.373 (1.246-4.521) | p = 0.532 | p = 0.012 |
| Cancer stage | | | T1-T2 | 35 | 81 | 58 | 58 | T3-T4 | 24 | 58 | 43 | 39 | | OR = 1.224 (0.664-2.256) | OR = 0.907 (0.515-1.597) | p = 0.624 | p = 0.841 |
|
|